Experimental evidence for limited in vivo virulence of Mycobacterium africanum by Cá, Baltazar et al.
fmicb-10-02102 September 6, 2019 Time: 18:1 # 1
ORIGINAL RESEARCH









The Gambia Unit (MRC), Gambia
Isaac Darko Otchere,
Noguchi Memorial Institute






This article was submitted to
Infectious Diseases,
a section of the journal
Frontiers in Microbiology
Received: 09 July 2019
Accepted: 26 August 2019
Published: 10 September 2019
Citation:
Cá B, Fonseca KL, Sousa J,
Maceiras AR, Machado D, Sanca L,
Rabna P, Rodrigues PNS, Viveiros M
and Saraiva M (2019) Experimental





Limited in vivo Virulence of
Mycobacterium africanum
Baltazar Cá1,2,3,4,5, Kaori L. Fonseca1,2,3,4, Jeremy Sousa1,2,4, Ana Raquel Maceiras1,2,
Diana Machado6, Lilica Sanca5, Paulo Rabna5, Pedro N. S. Rodrigues1,2,4,
Miguel Viveiros6 and Margarida Saraiva1,2*
1 i3S – Instituto de Investigação e Inovação em Saúde, Porto, Portugal, 2 Instituto de Biologia Molecular e Celular,
Universidade do Porto, Porto, Portugal, 3 Programa de Pós-Graduação Ciência para o Desenvolvimento, Instituto
Gulbenkian de Ciência, Oeiras, Portugal, 4 Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, Porto,
Portugal, 5 Instituto Nacional de Saúde Pública/Projeto de Saúde de Bandim, Bissau, Guinea-Bissau, 6 Global Health
and Tropical Medicine, Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa, Lisbon, Portugal
Tuberculosis remains a public health problem and a main cause of death to humans.
Both Mycobacterium tuberculosis and Mycobacterium africanum cause tuberculosis. In
contrast to M. tuberculosis, which is geographically spread, M. africanum is restricted
to West Africa. Differences have also been found in the growth rate and type of disease
caused by M. africanum, globally suggesting an attenuation of this bacteria. In this
study, we used the mouse model of infection to follow the dynamics of M. africanum
infection in terms of bacterial burdens and tissue pathology, as well as the immune
response triggered. Our findings support a lower virulence of M. africanum as compared
to M. tuberculosis, including in mice lacking IFN-γ, a major protective cytokine in
tuberculosis. Furthermore, the lung immune response triggered by M. africanum
infection in wild-type animals was characterized by a discrete influx of leukocytes and a
modest transcriptional upregulation of inflammatory mediators. Our findings contribute
to elucidate the pathogenesis of M. africanum, supporting the hypothesis that this is
an attenuated member of the tuberculosis-causing bacteria. Understanding the biology
of M. africanum and how it interacts with the host to establish infection will have
implications for our knowledge of TB and for the development of novel and better tools
to control this devastating disease.
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INTRODUCTION
Tuberculosis remains a global health problem, with approx. 10 million new cases and over
1.3 million deaths in 2017 (WHO, 2018). Both Mycobacterium tuberculosis and Mycobacterium
africanum can cause human TB (Brites and Gagneux, 2015). These TB-causing bacteria are in turn
divided into 7 L belonging to the MTBC, with L1, 2, 3, 4, and 7 encompassing M. tuberculosis sensu
Abbreviations: −/−, deficient; BMDM, bone marrow-derived macrophages; CFU, colony forming unit; DC, dendritic cell;
ESAT6, early secreted antigenic target, 6 kDa; H&E, hematoxylin and eosin; L, lineage; MOI, multiplicity of infection; MTBC,
Mycobacterium tuberculosis complex; PBMCs, peripheral blood mononuclear cells; TB, tuberculosis.
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stricto, and L5 and 6 encompassing M. africanum (Gagneux,
2018). Relevant diversity at genomic, clinical and immunological
level has been well documented for M. tuberculosis (Bastos et al.,
2017). Recent studies show that diversity within M. africanum L5
and L6 also exists (Ates et al., 2018; Otchere et al., 2018), but
its functional impact remains unknown. Interestingly, whereas
infections with M. tuberculosis are globally widespread, those
with M. africanum are geographically restricted to West Africa
(Yeboah-Manu et al., 2017). Indeed, isolation of M. africanum
from patients with TB in non-African countries has been
mostly restricted to migrants from endemic areas in Africa
(Isea-Pena et al., 2012).
The mechanisms underlying the restricted ecological niche
of M. africanum remain elusive. This restriction may result
from specific host-pathogen interactions, as supported by the
association of M. africanum L5 with TB patients of the Ewe
ethnicity in Ghana (Asante-Poku et al., 2015), and by the
presence of specific mutations in the genes encoding the ESX
secretion system in bacteria of L5 and L6, which could represent
adaptations to the niche of the West African host (Winglee et al.,
2016). Another possibility relies on M. africanum being zoonotic
with an animal reservoir limited to West Africa. Infection of
animals with M. africanum have been described (Thorel, 1980;
Alfredsen and Saxegaard, 1992; Gudan et al., 2008), and a novel
MTBC strain closely related to L6 has been isolated from a wild
chimpanzee (Coscolla et al., 2013). However, evidence of person
to person transmission of M. africanum has also been reported
(Winglee et al., 2016), thus suggesting that an animal reservoir is
not fully required. Finally, M. africanum may be an attenuated
member of the MTBC, and consequently outcompeted by
M. tuberculosis lineages, in most settings. This last hypothesis
is supported by several lines of evidence. Epidemiologically, a
decline on the incidence of M. africanum has been reported over
time for some countries (Dosso et al., 1999; Kallenius et al.,
1999; Koro Koro et al., 2013), although not for others (Gehre
et al., 2013; Yeboah-Manu et al., 2017). At the clinical level,
M. africanum has been associated with a slower progression to
disease than M. tuberculosis (de Jong et al., 2008), and reported
to be more commonly found in HIV, malnourished and older
individuals (de Jong et al., 2010a). The preferential association
of M. africanum with HIV remains, however debatable (Meyer
et al., 2008). Furthermore, several M. tuberculosis key virulence
mechanisms have been shown to be affected in M. africanum
(Yeboah-Manu et al., 2017). Such is the case of the DosR regulon
(Ofori-Anyinam et al., 2017), ESAT6 (de Jong et al., 2006),
and PhoP/R (Gonzalo-Asensio et al., 2014). Although scarcely
explored, data from experimental animal models also point to a
slower progression of disease upon infection with M. africanum
than that observed with M. tuberculosis (Bold et al., 2012; Wiens
and Ernst, 2016b).
Understanding the course of infection of M. africanum,
particularly the type of immune responses developed to this
member of the MTBC as compared to M. tuberculosis sensu
stricto, may shed light into novel strategies to tackle TB. In
this study, we followed the progression of experimental (mouse)
aerosol infection by a clinical isolate of M. africanum. As
compared to M. tuberculosis infections, the clinical isolate of
M. africanum under study was associated with lower bacterial
burdens, signs of disease and tissue pathology, even in hosts
lacking IFN-γ, a critical protective molecule in TB. Moreover, the
infection was accompanied by a modest cellular and molecular
immune response in the lungs of infected mice. Our findings
contribute to elucidate the pathogenic potential of M. africanum,
supporting the hypothesis that M. africanum is a less virulent
member of the TB-causing bacteria.
MATERIALS AND METHODS
Ethics Statement
Animal experiments were performed in strict accordance with
the recommendations of the EU Directive 2010/63/EU and
approved by the Portuguese National Authority for Animal
Health (DGAV-Ref. 0421/000/000/2016). Mice were kept with
food and water ad libitum and humanely euthanized by CO2
asphyxiation. Every effort was made to minimize suffering.
The human study that originated the blood samples for PBMC
isolation was reviewed and approved by the Portuguese Comissão
de Ética para a Saúde da ARS Norte (project T792). Written
informed consent was obtained for collection of biological
material and data from all study participants were anonymized.
Animals
Eight to twelve-week-old male and female C57BL/6 WT or IFN-γ
deficient (−/−) mice were bred and housed at i3S animal facility.
For infections, animals were housed under contention conditions
in the Animal Biosafety Level 3 facility at i3S.
Bacteria Isolation and Characterization
Mycobacterium africanum G67 (Maf_G67) was isolated in
Guinea-Bissau at the Instituto Nacional de Saúde Pública
(INASA) from a TB patient diagnosed and followed at the
Raoul Follereau Hospital, Bissau, Guinea-Bissau, in 2012 (Rabna
et al., 2015). It was grown on MGIT tubes for the BACTEC
MGIT 960 (Becton-Dickinson, Sparks, MD, United States)
according to the manufacturer’s instructions. The Genotype
MTBC assay (Hain Lifescience, Nehren, Germany) was used
for the differentiation within the MTBC as per manufacturer’s
instructions. First-line drug susceptibility testing was performed
using the proportion method with the MGIT 960 system,
according to the manufacturer’s instructions. Spoligotyping and
region of difference (RD) analysis were performed as previously
described (Kamerbeek et al., 1997; Rao et al., 2005). Maf_G67
was grown in 7H9 liquid media, supplemented with 10% oleic
acid, albumin, dextrose and catalase (OADC) for 7–10 days, with
0.05% Tween 80 for expansion. When in mid-log phase, bacterial
stocks were frozen at −80◦C in 1 ml aliquots in the presence
of 0.2% glycerol. Six aliquots were then thawed and used as
control for bacterial load determination by CFU enumeration.
The number of viable bacteria obtained after 2 weeks of freezing
was 1.7 × 108 CFU/mL, and after 28 weeks of freezing was
1.64 × 108 CFU/mL. Bacterial stocks were washed twice with PBS
before aerosol infections.
Frontiers in Microbiology | www.frontiersin.org 2 September 2019 | Volume 10 | Article 2102
fmicb-10-02102 September 6, 2019 Time: 18:1 # 3
Cá et al. Mycobacterium africanum Is Attenuated
In vitro Cultures and Infections
Mouse bone marrow-derived macrophages were differentiated
from bone marrow precursors in the presence of 20% L929 cell-
conditioned media (LCCM). Briefly, bone marrow cells were
plated at a concentration of 0.5 × 106 cells/mL in Sterilin
Petri dishes in 8 mL of DMEM supplemented with 10% FCS,
Glutamine, HEPES and sodium pyruvate and 20% LCCM. On
day 4, 10 mL of DMEM with all supplements were added and cells
were infected on day 7, at a MOI of 2 (Moreira-Teixeira et al.,
2016). THP-1 cells were grown following ATCC instructions,
differentiated with 100 nM PMA for 24 h and infected after a
48 h rest using a MOI of 1. Human PBMCs were separated using
Histopaque 1077 (Sigma-Aldrich, St. Louis, MO, United States)
following the protocol for mononuclear cell separation of
SepMate-50 tubes (StemCells, Vancouver, BC, Canada). Cells
were frozen and used on the infection day. A MOI of 1 was used,
which was calculated to match the total number of cells in culture
and which did not compromise cell viability during the infection
procedure. At the indicated time points, culture supernatants
were harvested and filter-sterilized for cytokine determination
by immunoassay (ELISA or Multiplex; eBioscience, Vienna,
Austria) or intracellular bacterial load enumeration, as performed
previously (Moreira-Teixeira et al., 2016).
Aerosol Infection and Bacterial Burden
Determination
Mice were infected with M. africanum via aerosol route
using an inhalation exposure system (Glas-Col, United States),
as described previously (Moreira-Teixeira et al., 2016). The
infection dose was obtained by determining the number of
viable bacteria in the lungs of 3–5 mice per experiment, 3 days
after infection (<200 CFU for low doses; >500 CFU for high
doses of infection). For lung bacterial load determination, organs
were aseptically excised, individually homogenized, and serial
dilutions plated for CFU enumeration (Moreira-Teixeira et al.,
2016). CFUs were counted after 21–28 days incubation at 37◦C.
Histology
Whole lungs were perfused in situ with PBS. The right upper
lobe was excised, fixed in 3.7% phosphate-buffered formalin
for 1 week, embedded in paraffin and cut into 3-mm-thick
sections, which were stained with H&E, as previously described
(Bhatt et al., 2018). Images were acquired with a NanoZoomer
2.0-HT Whole Slide Imager, Digital Pathology Slide Scanner
(Hamamatsu, Japan).
Cell Population Analysis by Flow
Cytometry
Lung single cell suspensions were obtained and stained for
surface antigens for 30 min at 4◦C. Stained cells were washed and
then fixed overnight in PBS containing 2% paraformaldehyde.
The following antibodies were used: αCD3-PE (clone 145-2C11,
eBioscience), αCD4-PB (clone RM4-5, eBioscience), αCD8-FITC
(clone 5H10-1, Biolegend, San Diego, United States), αCD19-
APC (clone eBio1D3, eBioscience), αLy6G-APC (clone 1A8,
Biolegend), αLy6C-PerCPCy5.5 (clone AL-21, BD Pharmingen),
αCD11b-PE (clone M1/70, Biolegend), and αCD11c-PB (clone
N418, Biolegend). Dead cells were excluded using Zombie Aqua,
a viability dye (Biolegend). All samples were analyzed on a
CANTO flow cytometer with Diva Software and data analyzed
using FlowJo version 10.1.r7 software. The gating strategies used
are shown in Supplementary Figure S1.
RNA Extraction and Analysis
Total RNA from infected lungs was extracted with TRIzol
Reagent (Invitrogen, CA, United States), according to the
manufacturer’s instructions. cDNA was synthesized using
the SuperScript First-Strand Synthesis System for RT-PCR
(ThermoScientific, United States). Target gene mRNA expression
was quantified by real-time PCR using SYBR Green (Thermo
Fisher) and normalized to ubiquitin mRNA levels, as described
before (Bhatt et al., 2018).
Statistics
Data were analyzed using GraphPad Prism software, version
8.1.0. Student’s t test was used to determine differences between
two different groups and one-way ANOVA for more than two
groups. Post-tests were applied to multiple comparisons as
referred in figure legends. Data was checked for normality and log
normality. Differences were considered significant for p ≤ 0.05
and represented as follows: ∗p ≤ 0.05; ∗∗p ≤ 0.01; ∗∗∗p ≤ 0.001,
and ∗∗∗∗p ≤ 0.0001.
RESULTS
Mycobacterium africanum Establishes a
Slow Progressing Infection With Minimal
Tissue Pathology in Immunocompetent
Mice
The mechanisms underlying the ecological restriction of
M. africanum remain unknown, but could be explained by
a relative lower virulence of M. africanum as compared to
M. tuberculosis. To gain experimental insight into this question,
we decided to investigate the progression of M. africanum
infection in mice. For this, we used a clinical isolate of
M. africanum belonging to L6 (AFRI_I), SIT181, and isolated
from a TB patient in Guinea Bissau (Rabna et al., 2015), a country
that shows the highest prevalence of M. africanum recorded in
the African continent (Groenheit et al., 2011). This clinical isolate
was susceptible to all five first-line anti-TB drugs. According
to the RD typing, Maf_G67 groups in M. africanum subtype
II and belongs to the Guinea-Bissau family (absence of RD7,
RD8, RD9, and RD10). As expected, the growth of Maf_G67 in
axenic medium was slower as compared to M. tuberculosis H37Rv
(Supplementary Figure S2).
We started by infecting macrophages with the M. africanum
clinical isolate under study. In vitro infection of mouse BMDM
showed persistence of this isolate over time (Figure 1A) and
triggered the secretion of both pro- and anti-inflammatory
cytokines (Figure 1B). Cytokine secretion was also observed
upon infection of PMA-differentiated THP1 cells, a human
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FIGURE 1 | Mycobacterium africanum triggers an immune response in mouse
and human cells. (A,B) BMDM were infected with M. africanum (Maf) at a MOI
of 2. (A) Four and 96 h later the intracellular bacterial load was determined by
CFU enumeration. Data is shown as mean ± SEM for three independent
experiments, each performed in 4–5 replicate wells. (B) Twenty-four hours
post-infection, the culture supernatants were harvested and cytokines
measured by immunoassay. Data is shown as mean ± SEM for three
independent experiments, each performed in triplicate wells. (C) THP1 cells
were differentiated in the presence of PMA, infected with M. africanum at a
MOI of 1 and 24 h later cytokine concentration determined by immunoassay.
(D) Human PBMCs were isolated, infected with M. africanum at a MOI of 1
and 24 h later cytokine concentration determined by immunoassay. Data is
shown as mean ± SEM for six independent donours. Non-infected (NI) cells
are included as controls. Unpaired t-test and Mann–Whitney test were used to
perform the statistical analysis. ∗p < 0.05; ∗∗∗∗p < 0.0001. bdl, below
detection level.
monocytic cell line (Figure 1C), or human PBMCs (Figure 1D).
The rational underlying the use of different cell types was to
test if the clinical isolate used in our study triggered a cytokine
response that was not dependent on the cell type. These data
show that the M. africanum clinical isolate infects, persists in and
is recognized by innate immune cells in spite of their different
origin and genetic background.
Next, we infected C57BL/6 WT mice with a high dose of
M. africanum via the aerosol route. A high dose of infection was
performed to probe the host ability to deal with M. africanum
under more extreme conditions than those associated with low
doses of infection. M. africanum was able to effectively infect
and persist in the mouse lungs, but the bacterial burden did
not increase significantly over time (Figure 2A). Moreover, the
bacterial burdens detected in the lung were substantially lower
than those observed in infections with M. tuberculosis reference
strains (L4, H37Rv; or L2, HN878) (Table 1). In spite of this poor
growth in the lung, M. africanum disseminated to the spleen and
liver over the 60-day time course (Figure 2A).
Tissue sections of M. africanum-infected lungs were examined
to assess pulmonary pathology. The extent of inflammatory
infiltrates and pathology observed in M. africanum-infected
animals was minimal (Figure 2B). In the case of M. tuberculosis
infections, multiple inflammatory foci with infiltration of
immune cells and perivascular lymphocyte recruitment was seen
(Supplementary Figure S3). These histopathological features,
which are characteristic of aerosol infections with high doses
of M. tuberculosis and accompanied by extensive tissue damage,
were mostly inexistent in the case of M. africanum infection. On
day 30 and 60 post-M. africanum infection, the lung tissue was
mostly preserved, except in limited areas where a modest immune
infiltration was noted (Figure 2B).
A Discrete Immune Response Develops
in the Lung Upon M. africanum Infection
In parallel, we investigated the recruitment of myeloid and
lymphoid immune cell populations to the lung of infected mice.
Overall the recruitment of immune cells was observed over time
(Figure 2C). Specifically, a significant, but modest, increase was
observed in the lungs of infected mice for recruited macrophages,
myeloid DCs, neutrophils, CD4, and CD8 T cells (Figure 2C).
This observation supports the activation of an immune response
upon M. africanum infection.
We also measured the transcription of several immune
mediators in the lung of M. africanum-infected mice. In line
with the modest immune cell recruitment observed (Figure 2C),
the transcription of the analyzed molecules was also discrete
(Figure 2D). Indeed, as compared to non-infected mice, there
was no significant upregulation of ifng or tnf (Figure 2D) and
the transcription of nos2 was undetected (data not shown).
A significant upregulation of il17 transcription was observed
(Figure 2D). Interestingly, in contrast to what was observed for
these pro-inflammatory mediators, the transcription of the anti-
inflammatory cytokine IL-10 was markedly upregulated during
infection (Figure 2D).
Altogether, these data are in line with the bacterial burden
and histology findings, which highlight infection in the lung with
limited immune activation and pathology.
Lack of IFN-γ Does Not Compromise the
Survival of Mice Infected With
M. africanum
Given our observations in M. africanum-infected C57BL/6
immunocompetent mice, we next questioned whether the
absence of a major protective molecule would impact the course
of infection by this pathogen. For that, we aerosol-infected
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FIGURE 2 | Mycobacterium africanum infection is controlled by
immunocompetent hosts, with minimal pathology and immune responses.
C57BL/6 mice were infected via aerosol with a high dose (>500 CFU) of
M. africanum. (A) At the indicated time points, the lungs, spleens, and livers of
infected mice were collected and the bacterial burden determined by CFU
enumeration. Lungs were harvested at the indicated time points and (B)
pathology determined by H&E staining; (C) immune cell populations
determined by flow cytometry; and (D) the expression of the indicated
cytokines measured by real-time PCR. Data are shown as mean ± SEM from
at least two independent experiments with five animals each. The images in
(B) are of one animal representative of the experimental group. Scale bar on
the left and right images correspond to 1 mm and 100 µm, respectively.
One-way ANOVA with Tukey’s post-test was used to perform the statistical
analysis. ∗p < 0.05; ∗∗,##p < 0.01; ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001. Asterisk
(∗) related to differences compared to NI mice, and hash (#) related to
differences comparing d30 to d60 post-infection.
TABLE 1 | Comparison of lung bacterial burdens obtained for infections with a
M. africanum clinical isolate versus M. tuberculosis reference strains HN878 and
H37Rv.
Low dose High dose
Log10CFU Log10CFU
d30 d60 d30 d60
M. africanum
(L6)
2.62 ± 0.022 2.45 ± 0.021 3.012 ± 0.129 2.89 ± 0.068
Mtb HN878
(L2)
6.078 ± 0.087 5.723 ± 0.110 7.453 ± 0.138 –
Mtb H37Rv
(L4)
4.866 ± 0.0898 5.024 ± 0.296 – 5.203 ± 0.314
C57BL/6 mice were infected via aerosol with a low (<200 CFU) or high dose
(>500 CFU) of the indicated bacteria and on day 30 or 60 post-infection the
lungs were collected and the bacterial burden determined by CFU enumeration.
Data are shown as mean ± SEM from at least five animals per time point. Mtb,
M. tuberculosis; L, lineage.
C57BL/6 WT or IFN-γ−/− mice with the M. africanum clinical
isolate under study and followed the progression of infection
over a period of 90 days. Considering the high susceptibility
of IFN-γ−/− mice to M. tuberculosis (Cooper et al., 1993;
Nandi and Behar, 2011; Moreira-Teixeira et al., 2016), we
decided to perform the infection with a low dose of bacteria.
Notably, IFN-γ−/− mice infected with M. africanum survived
for the duration of the experiment, showing no signs of weight
loss (Figure 3A). Furthermore, although the lung bacterial
burden was significantly increased in IFN-γ−/− infected mice, as
compared to WT ones, bacterial growth was still well controlled
(Figure 3B) and far from the typical values observed upon aerosol
infection of these mice with M. tuberculosis (Nandi and Behar,
2011; Moreira-Teixeira et al., 2016). As compared to C57BL/6
WT animals, a higher dissemination of M. africanum to the
spleen and liver of IFN-γ−/− mice was observed (Figure 3B).
Also, in IFN-γ−/− mice, a robust growth of M. africanum was
seen in these organs as compared to that observed in the lung. At
the histologic level, WT lungs showed no detectable signs of tissue
pathology (Figure 3C), showing that as compared to infections
with high doses of M. africanum (Figure 2B), upon a low
dose of infection a lesser infiltration of immune cells develops.
IFN-γ−/− mice infected with M. africanum presented signs of
immunopathology in the lung (Figure 3C), with well-localized
infiltrates surrounded by areas of healthy tissue.
Collectively, these data suggest that the lack of IFN impacted
the ability of mice to deal with M. africanum infection, but in
contrast to M. tuberculosis infections (Cooper et al., 1993; Nandi
and Behar, 2011; Moreira-Teixeira et al., 2016), it did not lead
to overt disease and premature death, at least during the first
90 days of infection.
DISCUSSION
Despite the close relationship between M. africanum and
M. tuberculosis, their biology, epidemiology, and potential to
cause disease is different, calling for the study of TB disease
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FIGURE 3 | IFN-γ is required for optimal control of M. africanum, but its
absence does not lead to overt disease. C57BL/6 WT (black circles or bars)
and IFN-γ−/− (white circles or bars) mice were infected by aerosol with a low
dose (<200 CFU) of M. africanum. (A) The weight of the animals was
monitored weekly up to day 90. On day 90 post-infection, (B) lungs, spleens,
and livers of infected mice were collected and the bacteria burden determined
by CFU enumeration and (C) lungs were harvested and pathology determined
by H&E staining. Data are shown as mean ± SEM from five animals per
group. The images in (C) are of one animal representative of the experimental
group. Scale bar on the left and right images correspond to 1 mm and
100 µm, respectively. Unpaired t-test was used to perform the statistical
analysis. ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001.
and associated immune responses to each bacteria. In this study,
we resorted to the mouse model to follow the progression of
infection by a clinical isolate of M. africanum in terms of bacterial
burden, tissue pathology and immune response triggered. Our
findings suggest a slow progressing of infection, with mild
lung pathology, even in typically highly susceptible hosts. The
M. africanum clinical isolate under study infected, persisted
and induced a cytokine response by mouse or human cells in
in vitro cultures, thus showing its ability to establish infection
and to actively interact with host immune cells. The persistence
of M. africanum in resting macrophages recapitulates previous
observations (Homolka et al., 2010).
Our in vivo data are compatible with a slower course of
infection of at least some isolates of M. africanum in the mouse
model, which is in line with what has been reported in humans
(de Jong et al., 2008) and also with two previously studies using
the mouse model (Bold et al., 2012; Wiens and Ernst, 2016b).
In one of these former studies (Bold et al., 2012), the reduction
of bacterial burden seen in the lungs of M. africanum-infected
animals, as compared to M. tuberculosis, was not as pronounced
as we report here. In our study and those previously published
(Bold et al., 2012; Wiens and Ernst, 2016b), the M. africanum
isolates used belonged to L6. However, whereas in our study the
clinical isolate has been obtained from a TB patient in Bissau,
the previous studies used a bacteria that had been isolated from
a TB patient in The Gambia (Bold et al., 2012; Wiens and
Ernst, 2016b). It is possible that the variations observed in terms
of reported bacterial burdens reflect the recently demonstrated
M. africanum intrapathogen diversity (Ates et al., 2018; Otchere
et al., 2018), and so that a spectrum of virulence exists among
M. africanum isolates. It will be important to address this possible
spectrum of M. africanum virulence, as it may explain several
apparent contradictory observations. For example, a possible
attenuation of M. africanum supports the likely outcompetition
of this pathogen by M. tuberculosis, as suggested by studies
reporting a decreased incidence of M. africanum over the time
(Koro Koro et al., 2013). However, in other geographic locations,
the incidence of M. africanum appears to be constant (Yeboah-
Manu et al., 2017; Asare et al., 2018) and a recent study including
3580 isolates from 12 different countries (Gehre et al., 2016) show
that M. africanum, particularly L6, remains a significant cause of
TB in West Africa.
Our findings reveal for the first time that infection with a
M. africanum clinical isolate causes a mild lung pathology upon
infection with a high dose of bacteria and over a 60 days period.
This is in sharp contrast to what we and others have observed
for infections with M. tuberculosis isolates and may reflect the
slow progression to TB disease described in humans infected
with M. africanum (de Jong et al., 2008), and also in some
animals (de Jong et al., 2010b). In turn, the slow progression
of M. africanum infection may be related to the delayed growth
described for these bacteria using in vitro methods (Gehre et al.,
2013) or to a certain impairment to grow in the lung, reflective
of a microaerobic preference developed by M. africanum when
compared to M. tuberculosis (Ofori-Anyinam et al., 2017). Our
observation is important as it suggests that, as compared with
M. tuberculosis infection, in humans infected with M. africanum,
lung damage and eventually cavitation may take a longer time
to develop. However, it is important to refer that at presentation
the disease caused by M. africanum is at least as severe as
that caused by M. tuberculosis (de Jong et al., 2007; Tientcheu
et al., 2016). Still, a slower progression to disease may eventually
compromise the transmission of M. africanum in the long term.
Indeed, a recent study showed that in Ghana the transmission
of M. africanum seems to be lower than that of M. tuberculosis
(Asare et al., 2018), whereas in Mali person to person recent
transmission has been reported (Winglee et al., 2016) and in The
Gambia similar rates of transmission between M. tuberculosis
and M. africanum have been described (de Jong et al., 2008).
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These variations may be related to the host and pathogen
intrinsic diversity.
Furthermore, we show the dissemination of this M. africanum
isolate to the spleen and liver of infected animals, where it
appears to grow somehow better than in the lung. Several
reasons may explain the dissemination of a bacteria that is
not growing well in the lung. On one hand, it is possible that
the lack of a robust T cell response may allow the escape of
more bacteria from the lung to other organs. In HIV-TB co-
infected patients, where CD4 T cell responses are lacking, a higher
dissemination of M. tuberculosis occurs (Aaron et al., 2004). On
the other hand, the more competent growth of M. africanum
in the spleen and liver, as compared to the lung, may be a
consequence of the downregulation of DosR and preference for
microaerobic growth described for this bacteria (Ofori-Anyinam
et al., 2017). In conclusion, our observations offer the hypothesis
that TB caused by M. africanum may be associated with higher
rates of extra-pulmonary or disseminated disease, as suggested
in a recent study (Sharma et al., 2016). They also indicate a
reduced degree of virulence of M. africanum, which may be
related to dissemination, rather than lung damage, during early
stages of infection.
Moreover, the control of this M. africanum isolate in the
mouse lung is reflected in the low recruitment of immune cells
and induction of cytokine transcription. Indeed, the transcription
of key cytokines as IFN-γ, IL-17, and TNF, as well as NOS2,
in the lungs of infected over non-infected mice was barely
detected. Noteworthy, however, was the robust transcription
of IL-10, which production was also seen in in vitro infected
mouse or human macrophages, and human PBMCs. It will be
interesting to, in the future, further dissect the mechanisms
regulating IL-10 expression upon infections with different
isolates of M. africanum, as well as to elucidate the possible
contribution of IL-10 for M. africanum pathogenesis, both
in the context of immunocompetent or immunocompromised
mice. Furthermore, it will be also interesting to establish
the dynamic of immune cell recruitment during the initial
phases of infection, when the innate immune responses are
likely predominant. Another outstanding question relates to
the mechanisms underlying the lower virulence associated
with M. africanum, which remain undisclosed. Of note,
the interaction of M. africanum with mouse macrophages
has been shown to differ from that of M. tuberculosis,
in what regards the transcriptional reprograming of the
bacteria (Homolka et al., 2010), as well as the triggering
of mitochondrial ROS and ultimately of type I IFN (Wiens
and Ernst, 2016a). How these observations articulate and
whether they may contribute to the lower virulence of
M. africanum is unknown.
The overwhelming protective nature of IFN-γ in TB has
been extensively described in mice and humans. IFN-γ−/− mice
infected with M. tuberculosis typically succumb to infection
during the first 40 days (Cooper et al., 1993; Nandi and
Behar, 2011; Moreira-Teixeira et al., 2016), whereas humans
with mutations in the IFN-γ producing/responding axis present
Mendelian susceptibility to mycobacterial disease (Abel et al.,
2018). Thus, the finding presented here for the first time that
mice lacking IFN-γ coped well with M. africanum aerosol
infection was most surprising. Still, it is important to refer
that although IFN-γ−/− mice survived a low dose infection
with this isolate of M. africanum for at least 90 days, they did
present higher lung bacterial burden and evidence for immune
pathology, not seen in IFN-γ competent mice. This indicates
that similar protective mechanisms operate among human-
adapted TB causing bacteria, albeit their required threshold
and dynamics for host protection are different. In the same
context, a recent report demonstrated that type I IFN receptor
signaling is detrimental during infections with a different isolate
of M. africanum (Wiens and Ernst, 2016b), as previously reported
for M. tuberculosis (Berry et al., 2010; Mayer-Barber et al.,
2014). Also, for both TB patients and household contacts,
M. africanum infection has been shown to elicit diminished
T cell responses to ESAT6, as compared to those elicited by
M. tuberculosis (de Jong et al., 2006). A subsequent study
identified higher proportion of single TNF and lower proportion
of single-IL-2-producing CD4 and CD8 T cells in M. africanum-
infected patients, as compared with M. tuberculosis-infected
ones before antibiotherapy, and persistently high proportion of
activated T cells in M. africanum infected patients after treatment
(Tientcheu et al., 2014).
In conclusion, several recent studies, including the one
presented here, are bridging the gap relatively to our
limited knowledge on M. africanum and pointing to an
overall lower virulence of these bacteria. The mechanisms
underlying this lower virulence are not fully understood,
highlighting the need for more research using diverse
M. africanum isolates, including those belonging to L5.
Understanding whether M. africanum is indeed less virulent
and the underlying causes, may shed important clues on
how to «attenuate» M. tuberculosis, either by targeting
the bacteria or the host immune response (Zumla et al.,
2017). Furthermore, a deep understanding of M. africanum
infections will inform the design of common or specific
vaccines and therapies.
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FIGURE S1 | Gating strategy used to delineate the cellular populations
present in the lung.
FIGURE S2 | In vitro growth rates of M. africanum G67 compared to
M. tuberculosis H37Rv. Bacterial suspensions were adjusted to 106 CFU/ml with
a sterile saline solution and 0.5 ml transferred into a MGIT tube containing 10%
OADC. Growth rates were measured at 37◦C with the MGIT 960 and the
Epicenter software for 28 days.
FIGURE S3 | Infection of C57BL/6 mice with a high dose of M. tuberculosis.
C57BL/6 mice were infected via aerosol with a high dose (>500 CFU) of
M. tuberculosis strain HN878. On day 30 post-infection, the lungs were collected
and pathology determined by H&E staining. The images are of one animal
representative of the experimental group (n = 5). Scale bar corresponds to 2.5 mm
on the left and 100 µm on the right panel.
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